Synlogic Stock News

Synlogic, Inc. (NASDAQ:SYBX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall IR Aoife Brennan - CEO, President Michael Jensen - CFO Tony A

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its pro

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its propri

Synlogic, Inc. (NASDAQ:SYBX ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall Investor Relations Aoife Brennan - Chief Executive Officer, Pres

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its pr

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2021 Results - Earnings Call Transcript

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its pr

Synlogic (SYBX) has appointed Michael Jensen as CFO. Mr

Synlogic Inc (SYBX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $142M. The stock is currently down 15.3% year-to-date, down 14.6% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 37.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2726.8% The company's stock price performance over the past 12 months beats the peer average by -8.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Brokerages expect Synlogic, Inc. (NASDAQ:SYBX) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Synlogics earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.24). Synlogic reported earnings of ($0.39) per share in the same quarter []